Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD finds support for Kinoko AHCC claims

This article was originally published in The Tan Sheet

Executive Summary

The mushroom-derived ingredient active hexose correlated compound shows immune-support benefits, though Quality of Life Labs should tweak its advertising language for Kinoko AHCC and Kinoko AHCC Gold, the National Advertising Division finds. The Purchase, N.Y.-based firm should clarify that data showing improved immune response and enhanced macrophage and T-cell activity are associated with the ingredient and not its products, the Council of Better Business Bureaus unit said May 28. Additionally, Quality of Life should revise its claim that the supplement is supported by "over 80 research studies," since NAD found the actual number was much lower, and should disclose that the immune benefits studied occurred in individuals with compromised immune systems. The company praised NAD's conclusions as "accurate and insightful" and said it will comply
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS102969

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel